Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03824912
Other study ID # 71875502
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date August 23, 2018
Est. completion date January 24, 2019

Study information

Verified date June 2019
Source Encube Ethicals Pvt. Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis


Description:

A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Encube Ethicals Pvt Ltd) to Ketoconazole Cream 2% (G&W Laboratories Inc.) in the Treatment of Tinea Pedis


Recruitment information / eligibility

Status Completed
Enrollment 831
Est. completion date January 24, 2019
Est. primary completion date January 24, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Healthy male or non-pregnant, non-lactating female, = 18 years of age.

2. Signed informed consent form (ICF) that meets all criteria of current Food and Drug Administration regulations.

3. Female patient of childbearing potential must not be pregnant or lactating at Visit 1 (as confirmed by a negative urine pregnancy test with a sensitivity of less than 50 milli-International unit (mIU/mL) or equivalent units of human chorionic gonadotropin).

4. Female patient of childbearing potential must agree to the use of a reliable method of contraception throughout the study (e.g., total abstinence, intrauterine device, a double-barrier method, oral, transdermal, injected, or implanted non-hormonal or hormonal contraceptive) throughout the study. A sterile sexual partner is not considered an adequate form of birth control. If the female is using any estrogen or oral contraceptive therapy, the same product must have been taken for at least one month before Visit 1.

5. Have clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot (the non-interdigital lesions should not be hyperkeratotic, i.e., characteristic of tinea pedis moccasin).

6. The presence of tinea pedis infection provisionally confirmed at baseline by a positive potassium hydroxide (KOH) wet mount preparation (i.e., skin scrapings from the target site are placed on a microscope slide with a drop of 10% KOH, and microscopic examination reveals segmented fungal hyphae).

7. The sum of clinical signs and symptoms scores of the target lesion = 4. See Appendix A for scoring scale:

1. Signs: Fissuring/cracking, erythema, maceration and scaling

2. Symptoms: pruritus and burning/stinging In addition the target lesion must have a minimum score = 2 for erythema and a minimum score = 2 for either pruritus or scaling.

Exclusion Criteria:

1. Females who are pregnant, lactating or planning to become pregnant during the study period.

2. History of or current psoriasis, Lichen planus or contact dermatitis involving the feet within the previous 12 months.

3. History of dermatophyte infections with a lack of response to antifungal therapy (recurrent tinea pedis [i.e., more than 3 infections in the past 12 months] that were unresponsive to previous antifungal therapy).

4. History of allergy, hypersensitivity, or intolerance to ketoconazole, other imidazoles, sulfites or any other component of the study product.

5. Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface.

6. Current uncontrolled diabetes.

7. Presence of any other infection of the foot or other disease process that, in the Investigator's opinion, may interfere with the evaluation of the patient's tinea pedis.

8. Known history of or current impaired wound healing, presence of peripheral vascular disease and/or trophic changes of the lower limbs to an extent that, in the opinion of the Investigator, would make the patient unsuitable for the study or compromise patient's safety.

9. Significant history or current evidence of chronic infectious disease, system disorder, organ disorder, immunosuppression (due to disease or therapy, including history of organ transplant), or other medical condition that, in the Investigator's opinion, would place the patient at undue risk by participating or compromise the integrity of the study data.

10. Use of antipruritics, including antihistamines, within 72 hours before Visit 1.

11. Use of topical corticosteroids, topical antibiotics or topical antifungal therapy (e.g., clotrimazole, econazole, fluconazole) within 2 weeks before Visit 1.

12. Use of systemic (e.g., oral or injectable) antibiotics, systemic antifungal therapy, or systemic corticosteroids within 30 days before Visit 1. The use of intranasal, inhaled or ophthalmic corticosteroids for acute or chronic conditions (e.g., allergic conjunctivitis, asthma/chronic obstructive pulmonary disease maintenance) is acceptable to the extent that, in the opinion of the Investigator, does not compromise safety of patient or integrity of data.

13. Use of oral terbinafine or itraconazole within 2 months before Visit 1.

14. Use of immunosuppressive medication or radiation therapy within 3 months before Visit 1.

15. Receipt of any drug as part of a research study within 30 days before Visit 1.

16. Previous participation in this study.

17. Employee of the Investigator or research center or their immediate family members.

18. Inability to understand the requirements of the study and the relative information or are unable or unwilling to comply with the study protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ketoconazole Cream 2%
Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
Ketoconazole Cream 2% (G&W Laboratories Inc.)
Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
Placebo
Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.

Locations

Country Name City State
Belize FXM Research International Belize City
Saint Lucia FXM Research International Castries
United States Long Beach Clinical Trial Services, Inc. Long Beach California
United States FXM Research Corp. Miami Florida
United States International Dermatology Research, Inc. Miami Florida
United States San Marcus Research Clinic, Inc. Miami Lakes Florida
United States FXM Research Miramar Miramar Florida
United States MOORE Clinical Research, Inc. Tampa Florida
United States PEAK Research, LLC Upper Saint Clair Pennsylvania

Sponsors (3)

Lead Sponsor Collaborator
Encube Ethicals Pvt. Ltd. ACM Global Laboratories, Novum Pharmaceutical Research Services

Countries where clinical trial is conducted

United States,  Belize,  Saint Lucia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Efficacy Endpoint: The Number of Patients in Each Treatment Group With a Therapeutic Cure of Tinea Pedis (Equivalence: Per-Protocol Population) Equivalence: Per-Protocol Population Therapeutic Cure: To be considered a Therapeutic Cure, the patient must have both Clinical and Mycological Cure of tinea pedis.
Therapeutic Failure: A patient will be considered a Therapeutic Failure if:
the patient is a Clinical or Mycological Failure
the patient was considered to have an insufficient therapeutic response
the patient used topical drug therapy for irritation or pruritus on the feet after the treatment phase of the study
Two weeks after the end of treatment (Day 56 ± 4) (Equivalence)
Primary Primary Efficacy Endpoint: The Number of Patients in Each Treatment Group With a Therapeutic Cure of Tinea Pedis (Superiority: Modified Intent-to-Treat Population) Superiority: modified Intent-to-Treat Population Therapeutic Cure: To be considered a Therapeutic Cure, the patient must have both Clinical and Mycological Cure of tinea pedis.
Therapeutic Failure: A patient will be considered a Therapeutic Failure if:
the patient is a Clinical or Mycological Failure
the patient was considered to have an insufficient therapeutic response
the patient used topical drug therapy for irritation or pruritus on the feet after the treatment phase of the study
Two weeks after the end of treatment (Day 56 ± 4) (Superiority)
Secondary Secondary Efficacy Endpoint: The Number of Patients in Each Treatment Group With a Clinical Cure of Tinea Pedis (Equivalence: Per-Protocol Population) Clinical Cure: To be considered a clinical cure the patient's total severity score must be = 2 with no individual severity score > 1.
Clinical Failure: A patient will be considered a Clinical Failure if the patient's total severity score is > 2 or any individual score is > 1.
Local Signs and Symptoms The most severely affected area will be identified as the target lesion at the baseline visit and will be used for the assessments at Day 42 and Day 56 visits.
The Clinical Signs and Symptoms of tinea pedis will be rated by the Investigator as "none", "mild," "moderate" or "severe" using the following standardized rating scale.
0 = None (complete absence of any sign or symptom)
= Mild (Slight)
= Moderate (Definitely Present)
= Severe (Marked, Intense)
The following signs and symptoms will be rated at each visit:
Signs: Fissuring/cracking, erythema, maceration, and scaling
Symptoms: Pruritus and burning/stinging
Two weeks after the end of treatment (Day 56 ± 4) (Equivalence)
Secondary Secondary Efficacy Endpoint:The Number of Patients in Each Treatment Group With a Mycological Cure of Tinea Pedis (Equivalence: Per-Protocol Population) Mycological Cure: To be considered a mycological cure the patient must have a negative Potassium hydroxide (KOH) test and a negative fungal culture.
Mycological Failure: A patient will be considered a Mycological Failure if the patient's KOH test is positive or the patient's fungal culture is positive.
Two weeks after the end of treatment (Day 56 ± 4) (Equivalence)
Secondary Secondary Efficacy Endpoint: The Number of Patients in Each Treatment Group With a Clinical Cure of Tinea Pedis (Superiority: Modified Intent-to-Treat Population) Clinical Cure: To be considered a clinical cure the patient's total severity score must be = 2 with no individual severity score > 1.
Clinical Failure: A patient will be considered a Clinical Failure if the patient's total severity score is > 2 or any individual score is > 1.
Local Signs and Symptoms The most severely affected area will be identified as the target lesion at the baseline visit and will be used for the assessments at Day 42 and Day 56 visits.
The Clinical Signs and Symptoms of tinea pedis will be rated by the Investigator as "none", "mild," "moderate" or "severe" using the following standardized rating scale.
0 = None (complete absence of any sign or symptom)
= Mild (Slight)
= Moderate (Definitely Present)
= Severe (Marked, Intense)
The following signs and symptoms will be rated at each visit:
Signs: Fissuring/cracking, erythema, maceration, and scaling
Symptoms: Pruritus and burning/stinging
Two weeks after the end of treatment (Day 56 ± 4) (Superiority)
Secondary Secondary Efficacy Endpoint:The Number of Patients in Each Treatment Group With a Mycological Cure of Tinea Pedis (Superiority: Modified Intent-to-Treat Population) Mycological Cure: To be considered a mycological cure the patient must have a negative Potassium hydroxide (KOH) test and a negative fungal culture.
Mycological Failure: A patient will be considered a Mycological Failure if the patient's KOH test is positive or the patient's fungal culture is positive.
Two weeks after the end of treatment (Day 56 ± 4) (Superiority)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05493488 - A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis Phase 2
Completed NCT04883593 - A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis. Early Phase 1
Terminated NCT02842021 - Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis Phase 2
Completed NCT01712360 - Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis Phase 4
Completed NCT00781664 - Cumulative Irritation Test Phase 1
Completed NCT03676686 - Study With Nåva Foot Cream in Patients With Tinea Pedis Interdigitalis N/A
Completed NCT01519752 - A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis Phase 1
Completed NCT03320486 - Non-inferiority Trial of Dapaconazole Versus Ketoconazole Phase 3
Completed NCT01580891 - Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis Phase 1
Completed NCT01353976 - Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis Phase 3
Completed NCT01349998 - Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis Phase 3
Completed NCT04265521 - Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry Feet N/A
Completed NCT02633813 - BE Study of Naftifine HCL Phase 3
Recruiting NCT00856596 - Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females Phase 3
Completed NCT00869336 - Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot) Phase 2
Completed NCT00768599 - A Study of Econazole Foam 1% in Athlete's Foot Phase 2
Recruiting NCT00233493 - Spread of Dermatophytes Among Families N/A
Completed NCT03897257 - A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis Phase 2
Completed NCT03129321 - Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis Phase 3
Completed NCT02335255 - Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis Phase 1